B

Bristol Myers Squibb

Makes drugs for cancer, blood and immune diseases

Executive Director - Neuroscience Global Commercial Strategy

Full-TimeUpdated on 10/24/2026Deadline 10/30/26
$239.1k - $289.7k+ Incentive cash + Stock opportunities
Expert
Bachelor's, MBA
Princeton, NJ, USA
HybridHybrid work model; domestic and international travel required (~20%).
Growth & MarketingProduct Marketing
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A BA/BS is required; a life sciences degree or equivalent experience is desirable, and an MBA or graduate degree is strongly preferred.
  • At least 12 years of progressive biopharmaceutical industry experience, including a record of leading products across the full asset life cycle from pipeline development through launch and in-market growth.
  • US and global experience is preferred.
  • Functional experience in psychiatry and neuroscience is strongly preferred.
  • Strong scientific and development acumen, including a sophisticated understanding of drug development, regulatory pathways, product design, evidence generation, and new product evaluation.
  • Deep understanding of commercial drug-development dimensions, including global and local market dynamics, operational feasibility, market access, patient advocacy, regulatory requirements, and reimbursement challenges across domestic and international markets.
  • Ability to collaborate across the enterprise and integrate internal and external stakeholder perspectives into commercial strategy and planning.
  • Demonstrated marketing experience.
  • Ability to critically assess opportunities with disciplined strategic judgment, determine what is best for patients and the business, and influence alignment across senior stakeholders.
  • Strong financial and business acumen, including synthesizing complex information, shaping investment recommendations, managing budgets, and delivering against financial targets.
  • Proven record of enterprise impact, breadth and depth across core marketing capabilities, and consistent achievement of performance objectives.
  • Experience setting strategic direction, communicating with executive presence, and creating a strong, inclusive, and energizing culture consistent with BMS values.
  • Experience mobilizing matrix teams, creating alignment in complex cross-functional environments, and leading through influence without direct authority.
Responsibilities
  • Set strategic direction for the global brand, mobilize cross-functional matrix partners, and engage priority markets to translate enterprise strategy into high-impact execution.
  • Lead strategies to optimize global brand performance and life-cycle value for KarXT.
  • Provide senior commercial leadership for KarXT, partnering with Development, Medical, Regulatory, CMC, Commercial, and Strategy & Operations to shape an integrated development and launch strategy.
  • Work with key markets, Business Insights & Analytics, and Global Market Access to ensure development decisions are grounded in market insight, customer needs, and clear paths to global commercialization.
  • Translate global strategy into market-level impact, with a focus on launch readiness, brand performance, and long-term value creation.
  • Identify and advance opportunities within and beyond the organization to strengthen KarXT’s global growth trajectory.
  • Serve as commercial lead on the KarXT Global Product Team and own the commercial vision, priorities, and decision-making agenda for the asset.
  • Establish strategic platforms to optimize KarXT, anticipate future market needs, and enable markets to launch with excellence.
  • Guide market-facing strategy, support customer engagement, and partner with medical colleagues to deepen external relationships with patient advocacy organizations, medical societies, and global thought leaders.
  • Define and scale BMS’s ex-US and global presence in emerging neuroscience disease areas, including schizophrenia, bipolar I mania/mixed, Alzheimer’s disease psychosis, agitation and cognition, and irritability in autism spectrum disorder.
  • Set commercialization strategies, assess customer and market dynamics, optimize brand positioning, and prepare launches in a high-value therapeutic area of strategic importance to BMS.
  • Lead long-range planning for the assets, contribute to building BMS’s global corporate presence in neuroscience, and guide products through major investment decisions, including representing and making recommendations to Executive Management.
  • Lead worldwide brand planning for priority neuroscience assets across marketing, medical, access, and development, including long-range strategic and financial planning.
  • Assess competitive intelligence, market events, and emerging scientific and commercial trends at the enterprise level; translate implications into brand strategies and investment priorities in rapidly evolving spaces that are new to BMS.
  • Convert emerging clinical, market, and brand evidence into strategic choices that maximize asset value, support appropriate patient use, and leverage artificial intelligence to drive insight and efficiency.
  • Build and steward strategic relationships with opinion leaders, advocacy organizations, external agencies, vendors, and other stakeholders to reinforce BMS’s commitment and establish leadership in key therapeutic areas.
  • Partner with Global Market Access and Pricing teams to shape development strategies that address future access requirements and enable strong launch uptake across priority markets.
  • Develop a deep understanding of local market dynamics, customer needs, payer considerations, and competitive forces to identify growth opportunities and inform global development and launch planning.
  • Lead through influence across functions, geographies, and senior levels to align development and launch strategies that drive commercial success.
  • Define strategies and cultivate stakeholder relationships that strengthen BMS’s presence and credibility in emerging neuroscience therapeutic areas.
  • Operate effectively in a fast-paced, high-accountability environment while delivering strategic quality, enterprise leadership, and execution excellence; influence senior stakeholders, align cross-functional teams, and lead through ambiguity across Clinical, Regulatory, Country Marketing, Market Access, and Commercial partners.
  • Travel domestically and internationally approximately 20% of the time.
Desired Qualifications
  • A life sciences degree or equivalent experience.
  • An MBA or graduate degree.
  • US and global experience.
  • Functional experience in psychiatry and neuroscience.

About the company

Bristol Myers Squibb discovers, develops and sells prescription medicines for serious illnesses, including cancer, blood disorders, immune diseases and heart disease, for patients treated by doctors and hospitals around the world. Its best-known drug is Opdivo, an immunotherapy that helps the body's own immune system find and attack many kinds of cancer. Researchers develop drug candidates in its labs or bring them in through acquisitions and partnerships, then test them in clinical trials to win regulatory approval. The company makes and markets the approved medicines and earns its revenue from sales of patent-protected drugs. Its roots go back to a business founded in 1887, and it is based in Lawrence Township, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lawrence Township, New Jersey

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are beating forecasts: BMS raised 2026 revenue guidance to $49 billion to $50 billion in July 2026.
  • Newer drugs carry the business: they made $7.6 billion of $13.0 billion in sales in the June 2026 quarter.
  • Manufacturing careers are expanding: a $2.3 billion Houston campus announced in August 2026 will add nearly 500 skilled roles.

What critics are saying

  • Job security is shaky: BMS added 265 New Jersey layoffs in September 2026, bringing its 2026 state cuts to 718.
  • A patent cliff looms: Eliquis and Opdivo, its two biggest drugs, lose US exclusivity around 2028.
  • Older drugs are shrinking fast: Revlimid sales fell 49% to $425 million in the June 2026 quarter as generics spread.

What makes Bristol Myers Squibb unique

  • BMS owns a psychiatry first: Cobenfy treats schizophrenia without blocking dopamine, unlike antipsychotics used for decades.
  • Its top seller is shared: BMS splits Eliquis blood thinner profits roughly equally with Pfizer in most markets.
  • BMS reengineers patients' own immune cells: it sells two CAR T therapies, Breyanzi and Abecma, for blood cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

8%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Oct 23rd, 2026
Three defensive stocks to buy as AI selloff hits: BMY, Colgate and Gilead offer dividends

As investors question the costs and returns of the AI boom, some are turning to defensive stocks in healthcare and consumer goods. Three that pay quarterly dividends stand out: Bristol Myers Squibb, Colgate-Palmolive, and Gilead Sciences. Bristol Myers Squibb shares are up 14.3% this year, with a forward dividend yield of 4.3% and 18 straight years of increases. Second-quarter revenue reached $13 billion, with newer products making up nearly 60%. Colgate-Palmolive is up 20.2% this year and has raised its dividend for 64 years in a row. It reported second-quarter revenue of $5.36 billion. Gilead shares have gained 26%, against 13% for the S&P 500. Second-quarter HIV sales rose 12% to $5.7 billion.

Market Chameleon
Oct 19th, 2026
Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026.

Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026. 19 October 2026, 8:50 AM By Market Chameleon Produced with AI assistance and reviewed by Market Chameleon staff. Bristol Myers Squibb (BMY) said it will present new data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) 2026 Congress (October 23-27 in Madrid), spanning 12 oral presentations and nearly 60 disclosures. The company's update spotlights multiple modalities across solid tumors, including late-breaking Phase 3 studies for izalontamab brengitecan (iza-bren) and late-breaking global Phase 2 data for pumitamig, alongside long-term survival results for Opdivo plus Yervoy. ESMO 2026 presence emphasizes late-breaking Phase 3 and Phase 2 catalysts across solid tumors. In the announcement, Bristol Myers highlighted two late-breaking, Phase 3 studies of izalontamab brengitecan (iza-bren), described as a potential first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01).

Savills
Oct 14th, 2026
San diego Q3 2026 life sciences market report.

San diego Q3 2026 life sciences market report. 14 October 2026 Market highlights. * Overall vacancy increased 60 basis points year over year to 28.5% in Q3 2026, up from 27.9% in Q3 2025. The increase was driven by direct vacancy, which rose to 25.8%, while sublease vacancy declined to 2.8%. * Venture capital funding slowed considerably in 2026, with $1.4 billion raised across 113 deals through Q3, down 34.1% year over year and marking the lowest Q1 through Q3 total since 2022. * Alexandria Real Estate delivered a 427,000-square-foot R&D hub for Bristol Myers Squibb at Campus Point, establishing the company as an anchor tenant at the 2.9- million-square-foot life sciences campus.

Yahoo Finance
Oct 13th, 2026
Eli Lilly beats Bristol Myers Squibb on growth: $65.2B revenue, 45% rise vs. $48.2B

A comparison of Bristol Myers Squibb and Eli Lilly concludes that Lilly is the better healthcare stock to buy in 2026, even at a premium. Lilly's 2025 revenue rose about 45% to $65.2 billion, with net income near $21 billion. Bristol Myers' revenue slipped 0.2% to $48.2 billion, though it returned to a net income of $7.1 billion after an $8.9 billion loss in 2024. Lilly trades at 33.8 times forward earnings against 8.2 times for Bristol Myers. The article says Bristol Myers is cheap for good reason, citing pricing pressure, patent expiries, and an unpredictable recovery. Lilly's weight-loss drugs Zepbound and Mounjaro are expected to lift 2026 revenue above 30%, to $88.6 billion. Bristol Myers is forecast to grow 3% to $49.9 billion.

Chinese LGZ
Oct 9th, 2026
Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility.

Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility. Source link: https://houston365.info/2026/10/09/bristol-myers-squibb-unveils-2-3-billion-investment-in-cutting-edge-houston-pharma-facility/ Bristol Myers Squibb strengthens Houston's life sciences sector with $2.3 billion facility. Bristol Myers Squibb is set to transform Houston's pharmaceutical landscape through a landmark $2.3 billion investment in a cutting-edge manufacturing plant. This initiative, developed in collaboration with the Greater Houston Partnership, aims to elevate the company's production capabilities while cementing Houston's status as a burgeoning center for biopharmaceutical innovation. The project is projected to generate hundreds of skilled jobs and stimulate substantial economic growth within the region. Project overview and strategic importance. The new facility will incorporate the latest manufacturing technologies to optimize efficiency and product quality. With over 1,200 new roles anticipated in scientific research, engineering, and production, the plant will serve as a catalyst for workforce development and community engagement. This expansion aligns with Bristol Myers Squibb's vision to accelerate the delivery of novel therapies and reinforces Houston's growing influence in the life sciences ecosystem. * Innovative manufacturing processes: Adoption of advanced automation and quality control systems. * Employment opportunities: Creation of more than 1,200 specialized jobs across multiple disciplines. * Community collaboration: Strengthening partnerships with local universities and healthcare institutions to foster innovation. | Investment Detail | Information | | Total... | - - Author: Samuel Brown Publish date: 2026-10-09 15:23:00 Copyright for syndicated content belongs to the linked Source. - - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8